Data from the phase 3 Microplasmin for Intravitreous Injection–Traction Release Without Surgical Treatment (MIVI-TRUST) studies described nonsurgical achievement of macular hole closure as a secondary outcome in 106 patients treated with a single injection of ocriplasmin compared with vehicle injection (40.6% vs 10.6%; P < .001).1 As options for macular hole treatment have expanded with pharmacologic vitreolysis, ongoing monitoring of these patients is prudent and important to further refine risk/benefit profiles.
Khan MA, Shahlaee A, Ho AC. Reopening of a Full-Thickness Macular Hole 2 Years After Pharmacologic Closure With Ocriplasmin. JAMA Ophthalmol. 2015;133(11):1362-1364. doi:10.1001/jamaophthalmol.2015.3331